DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations”

Status

Not yet recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525268-16-00

Enrollment

962

Registered

2026-10-19

Start date

Unknown

Completion date

Unknown

Last updated

2026-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Brief summary

PFS2 at two years is the primary endpoint of the study

Detailed description

OS, ORR, DoR, TRAEs, HRQoL

Interventions

DRUGLazcluze 240 mg film-coated tablets

DRUGTafinlar 50 mg hard capsules

DRUGVinorelbina Aurobindo 10 mg/ml concentrato per soluzione per infusione.

DRUGOPDIVO 300 mg solution for injection

DRUGTecentriq 1 875 mg solution for injection

DRUGLorviqua 25 mg film-coated tablets

DRUGMektovi 15 mg film-coated tablets

DRUGLIBTAYO 350 mg concentrate for solution for infusion.

DRUGOSIMERTINIB

DRUGRetsevmo 80 mg hard capsules

DRUGBraftovi 50 mg hard capsules

DRUGTecentriq 1 200 mg concentrate for solution for infusion

DRUGYERVOY 5 mg/ml concentrate for solution for infusion

DRUGLUMYKRAS 120 mg film-coated tablets

DRUGLazcluze 80 mg film-coated tablets

DRUGPaclitaxel Fresenius Kabi 6 mg/ml koncentrat till infusionsvätska

DRUGlösning

DRUGMektovi 45 mg film-coated tablets

DRUGRetsevmo 40 mg hard capsules

DRUGAlunbrig 90 mg film-coated tablets

DRUGRybrevant 1600 mg solution for injection

DRUGCisplatin Sandoz 0

DRUG5 mg/ml koncentrátum oldatos infúzióhoz

DRUGGemcitabina Aurobindo Pharma Italia 40 mg/ml concentrato per soluzione per infusione

DRUGRybrevant 2240 mg solution for injection

DRUGAlunbrig 30 mg film-coated tablets

DRUGTEPMETKO 225 mg film-coated tablets

DRUGAlunbrig 180 mg film-coated tablets

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion.

DRUGRybrevant 350 mg concentrate for solution for infusion.

DRUGKRAZATI 200 mg film-coated tablets

DRUGAlecensa 150 mg hard capsules

DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.

DRUGMekinist 0.5 mg film-coated tablets

DRUGTabrecta 200 mg film-coated tablets

DRUGMekinist 2 mg film-coated tablets

DRUGCarboplatin Pfizer 450 mg Konzentrat zur Infusionsbereitung

DRUGTabrecta 150 mg film-coated tablets

DRUGDocetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung

DRUGPemetrexed EVER Pharma 25 mg/ml koncentrat till infusionsvätska

DRUGLorviqua 100 mg film-coated tablets

DRUGBraftovi 75 mg hard capsules

DRUGTafinlar 75 mg hard capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
PFS2 at two years is the primary endpoint of the study	—

Secondary

Measure	Time frame
OS, ORR, DoR, TRAEs, HRQoL	—

Outcome results

None listed

Source: EU CTIS · Data processed: Oct 20, 2026